Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Financing Activities (2022 - 2025)

Zentalis Pharmaceuticals has reported Cash from Financing Activities over the past 4 years, most recently at -$4.6 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at -$4.6 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$4.3 million (down 4064.81% YoY), and the annual figure for FY2025 was -$4.3 million, down 4064.81%.
  • Cash from Financing Activities for Q4 2025 was -$4.6 million at Zentalis Pharmaceuticals, down from $115000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ZNTL hit a ceiling of $236.6 million in Q2 2023 and a floor of -$4.6 million in Q4 2025.
  • Median Cash from Financing Activities over the past 4 years was $309000.0 (2023), compared with a mean of $38.0 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 100.0% in 2024 and later skyrocketed 2600.0% in 2025.
  • Zentalis Pharmaceuticals' Cash from Financing Activities stood at $49.7 million in 2022, then tumbled by 99.38% to $309000.0 in 2023, then tumbled by 70.23% to $92000.0 in 2024, then crashed by 5084.78% to -$4.6 million in 2025.
  • The last three reported values for Cash from Financing Activities were -$4.6 million (Q4 2025), $115000.0 (Q3 2025), and $189000.0 (Q1 2025) per Business Quant data.